Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665607 | 1.00 | BTK (0.43) | BTKCDK1KDRCDK7MAPK1 | |
| SCHEMBL21397349 | 0.82 | BTK (0.41) | BTKCDK7MAPK1JAK1MAPK8 | |
| SCHEMBL16665652 | 0.82 | BTK (0.41) | BTKCDK7MAPK1JAK1MAPK8 | |
| SCHEMBL16665663 | 0.81 | BTK (0.47) | BTKCDK7MAPK1JAK1JAK2 | |
| SCHEMBL18074058 | 0.81 | BTK (0.47) | BTKCDK7MAPK1JAK1JAK2 | |
| SCHEMBL21397324 | 0.78 | CDK1 (0.45) | CDK1KDRCDK7CDK9CCNH | |
| SCHEMBL16665608 | 0.78 | CDK1 (0.45) | CDK1KDRCDK7CDK9CCNH | |
| SCHEMBL21397214 | 0.78 | BTK (0.45) | BTKCDK7MAPK1JAK1JAK2 | |
| SCHEMBL16665714 | 0.78 | BTK (0.45) | BTKCDK7MAPK1JAK1JAK2 | |
| SCHEMBL16665591 | 0.78 | CDK12 (0.51) | CDK7MAPK8MAPK9MAPK10CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | BTK 3043/4885CDK1 6/4885KDR 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.